Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients

Acta Diabetologica

Volumn 50, Issue 6, 2013, Pages 943-949

  Fadini, Gian Paolo ^a   Simioni, Natalino ^b   Frison, Vera ^b   Dal Pos, Michela ^b   Bettio, Michela ^b   Rocchini, Paola ^b   Avogaro, Angelo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b Diabetology Service   (Italy)

Author keywords

GLP 1; Incretin; Metabolic syndrome; Obesity; Therapy

Indexed keywords

ACARBOSE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; REPAGLINIDE; SERENIC AGENT;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG EFFECT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OUTPATIENTS; WEIGHT LOSS;

EID: 84890571759     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-013-0489-3     Document Type: Article

References (15)

1. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577-1596
2. Niswender K, Pi-Sunyer X, Buse J et al (2013) Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab 15:42-54
3. Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
4. van Genugten RE, Moller-Goede DL, van Raalte DH, Diamant M (2012) Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabetes Obes Metab (in press)
5. Fadini GP, de Kreutzenberg SV, Gjini R, Avogaro A (2011) The metabolic syndrome influences the response to incretin-based therapies. Acta Diabetol 48:219-225
6. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3:153-165
7. Jelsing J, Vrang N, Hansen G et al (2012) Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight. Diabetes Obes Metab 14:531-538
8. Hoyda TD, Smith PM, Ferguson AV (2009) Gastrointestinal hormone actions in the central regulation of energy metabolism: potential sensory roles for the circumventricular organs. Int J Obes (Lond) 33(Suppl 1):S16-S21
9. Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112:2735-2752
10. Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39-47
11. Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E (2012) Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res 2012:672658
12. Garber A, Henry RR, Ratner R et al (2011) Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 13:348-356
13. Deacon CF, Mannucci E, Ahren B (2012) Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes- A review and meta analysis. Diabetes Obes Metab 14:762-767
14. Chambers AP, Jessen L, Ryan KK et al (2011) Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 141:950-958
15. Valderas JP, Irribarra V, Rubio L et al (2011) Effects of sleeve gastrectomy and medical treatment for obesity on glucagon-like peptide 1 levels and glucose homeostasis in non-diabetic subjects. Obes Surg 21:902-909